Newsroom
Urovalve Awarded Phase 2 SBIR Grant for research to develop Novel Urethral Catheter
JUNE 15, 2007
Newark, N.J., June 15, 2007 - Urovalve, Inc., an early stage medical device company, has been awarded a $740,000 grant from the National Institutes of Health (NIH). The award will fund human testing of Urovalve's lead device for treating urinary retention.
"This device is intended to improve quality of life and decrease the high incidence of related health problems for men who must rely on catheters to relieve urinary retention" says Harvey D. Homan, President & CEO of Urovalve, Inc. “The valved-catheter is designed to be inserted into the urethra without surgery and return urinary control to the user for 28 days before requiring replacement. It will free users from reliance on current low-technology devices that limit activities, impose dependence on others, damage the self-image of users and cause a high incidence of serious urinary tract infections (UTI). Catheter-associated UTIs affect approximately 840,000 U. S. patients annually in acute care facilities at a cost of more than $1 billion per year."
The award, granted under the Small Business Innovative Research program (SBIR), is being funded by the National Institute of Child Health and Human Development (NICHD), an institute of NIH that supports and conducts research and research training to ensure the health, productivity, independence, and well-being of all people through optimal rehabilitation.
About Urovalve, Inc.
Urovalve, Inc. (www.urovalve.com) is a privately held company located in the Enterprise Development Center at New Jersey Institute of Technology in Newark, New Jersey. The company develops superior medical devices to address problems with urinary flow and control.